HomeCompareCMAKY vs ABBV

CMAKY vs ABBV: Dividend Comparison 2026

CMAKY yields 4.55% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $80.0K in total portfolio value
10 years
CMAKY
CMAKY
● Live price
4.55%
Share price
$4.85
Annual div
$0.22
5Y div CAGR
-6.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$285.48
Full CMAKY calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CMAKY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMAKYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMAKY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMAKY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMAKY
Annual income on $10K today (after 15% tax)
$386.46/yr
After 10yr DRIP, annual income (after tax)
$242.66/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,624.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMAKY + ABBV for your $10,000?

CMAKY: 50%ABBV: 50%
100% ABBV50/50100% CMAKY
Portfolio after 10yr
$64.7K
Annual income
$13,005.60/yr
Blended yield
20.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CMAKY
No analyst data
Altman Z
-0.6
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMAKY buys
0
ABBV buys
0
No recent congressional trades found for CMAKY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMAKYABBV
Forward yield4.55%3.12%
Annual dividend / share$0.22$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-6.6%40.6%
Portfolio after 10y$24.7K$104.7K
Annual income after 10y$285.48$25,725.73
Total dividends collected$3.6K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CMAKY vs ABBV ($10,000, DRIP)

YearCMAKY PortfolioCMAKY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,125$424.65$11,559$438.51$434.00ABBV
2$12,316$412.37$13,494$640.86$1.2KABBV
3$13,576$398.49$15,951$945.97$2.4KABBV
4$14,910$383.45$19,152$1,413.89$4.2KABBV
5$16,321$367.59$23,443$2,146.38$7.1KABBV
6$17,815$351.24$29,391$3,321.96$11.6KABBV
7$19,397$334.66$37,948$5,265.87$18.6KABBV
8$21,073$318.06$50,795$8,596.74$29.7KABBV
9$22,849$301.62$71,034$14,549.41$48.2KABBV
10$24,734$285.48$104,715$25,725.73$80.0KABBV

CMAKY vs ABBV: Complete Analysis 2026

CMAKYStock

China Minsheng Banking Corp., Ltd. provides various financial products and services to individuals, small and micro-enterprises, corporate customers, government agencies, and financial institutions in the People's Republic of China. The company operates through Corporate Banking, Retail Banking, and Others segments. Its deposit products include saving accounts, deposit certificates, contracted deposits, agreement deposits, call deposits, corporate term deposits, and corporate current deposits. The company also offers personal housing mortgage, individual automobile purchase, household composite consumption, home, medium and long term, and short-term working capital loans; micro-credit products for individuals; debit and credit cards; and safe deposit boxes. In addition, it provides payment and collection, and clearing services, as well as internet, mobile, and telephone banking services. Further, the company offers gross settlement; wages distribution agency and letter of guarantee; cash management; trade finance; industrial chain finance; individual forex settlement, forex remittance, travelers promissory notes, collection, individual deposit certificate, and guarantee letter products; and comprehensive credit granting, forex settlement and sale, financial product investment, and trust financing services. Additionally, it provides convenient finance, investment banking, and asset management services, as well as non-financial services in the education, business travel, traveler, art, luxury life, health, club, and isports areas. As of December 31, 2021, the company has approximately 140 branch-level institutions, 1,193 business outlets, 1,078 community sub-branches, and 136 small business sub-branches. China Minsheng Banking Corp., Ltd. was founded in 1996 and is headquartered in Beijing, the People's Republic of China.

Full CMAKY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CMAKY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMAKY vs SCHDCMAKY vs JEPICMAKY vs OCMAKY vs KOCMAKY vs MAINCMAKY vs JNJCMAKY vs MRKCMAKY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.